Atin Sharma (He/Him)

Postdoc, MIMS, Umeå Univeristy
  • Sweden

About Atin Sharma

I am a molecular biologist who loves to write and draw.

Subject Areas

Cell and Molecular Biology Infectious Diseases Science Communication

Intro Content

FDA approval for CRISPR/Cas9-based therapy for SCD – an accomplishment for science, not for majority of the patients.

The news of the FDA approving the world's first CRISPR/Cas9-based therapy for SCD is all over the internet. This is my opinion on what this achievement means for science and the majority of patients dealing with SCD.


Channels contributed to:

News and Opinion